Charles River investing in expanded biologics partnership with PathoQuest

16-Apr-2018 - Last updated on 16-Apr-2018 at 16:27 GMT

(Image: Getty/Ca-ssis)

Charles River Laboratories and PathoQuest have expanded their strategic partnership to help move vaccine, biologic, and gene-therapy candidates through the drug discovery and development pipeline.

“The expanded partnership with PathoQuest provides our biologics clients with access to PathoQuest’s next-generation sequencing (NGS) technology,” said Greg Beattie, ‎corporate vice president of global biologics testing solutions at ‎Charles River Laboratories.

PathoQuest’s technology combines a proprietary sample preparation method, equipment, and a curated pathogen database with a comprehensive BioIT analysis pipeline, Beattie explained.

The NGS solution is “a powerful test for identifying adventitious agents in a single, comprehensive analysis that minimizes false negatives while also providing a tool for the genetic characterization of cell lines,” he told us.

Charles River will also make a direct investment in PathoQuest as part of the expanded partnership.

“We are excited to offer our customers an industry-leading technology to help progress their vaccine, biologic and gene-therapy candidates through the drug discovery and development pipeline,” Beattie added.

“Working with PathoQuest, we are able to leverage our existing GLP and GMP capabilities with their NGS technology to offer a customized, fast, reliable and cost-effective solution.”